186 related articles for article (PubMed ID: 38116719)
1. Novel proteomic technologies to address gaps in pre-clinical ovarian cancer biomarker discovery efforts.
Jordan HA; Thomas SN
Expert Rev Proteomics; 2023; 20(12):439-450. PubMed ID: 38116719
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
3. A Targeted Mass Spectrometry Strategy for Developing Proteomic Biomarkers: A Case Study of Epithelial Ovarian Cancer.
Hüttenhain R; Choi M; Martin de la Fuente L; Oehl K; Chang CY; Zimmermann AK; Malander S; Olsson H; Surinova S; Clough T; Heinzelmann-Schwarz V; Wild PJ; Dinulescu DM; Niméus E; Vitek O; Aebersold R
Mol Cell Proteomics; 2019 Sep; 18(9):1836-1850. PubMed ID: 31289117
[TBL] [Abstract][Full Text] [Related]
4. Optomechanical devices for deep plasma cancer proteomics.
Kosaka PM; Calleja M; Tamayo J
Semin Cancer Biol; 2018 Oct; 52(Pt 1):26-38. PubMed ID: 28867489
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
Boyce EA; Kohn EC
Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
[TBL] [Abstract][Full Text] [Related]
6. Proteomic analysis for early detection of ovarian cancer: a realistic approach?
Stevens EV; Liotta LA; Kohn EC
Int J Gynecol Cancer; 2003; 13 Suppl 2():133-9. PubMed ID: 14656269
[TBL] [Abstract][Full Text] [Related]
7. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
8. Proteomic profiling in ovarian cancer.
Kim G; Minig L; Kohn EC
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of mass spectrometry in cancer biomarker discovery.
Wang P; Whiteaker JR; Paulovich AG
Cancer Biol Ther; 2009 Jun; 8(12):1083-94. PubMed ID: 19502776
[TBL] [Abstract][Full Text] [Related]
10. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
Pitteri SJ; JeBailey L; Faça VM; Thorpe JD; Silva MA; Ireton RC; Horton MB; Wang H; Pruitt LC; Zhang Q; Cheng KH; Urban N; Hanash SM; Dinulescu DM
PLoS One; 2009 Nov; 4(11):e7916. PubMed ID: 19936259
[TBL] [Abstract][Full Text] [Related]
11. Aptamer-based multiplexed proteomic technology for biomarker discovery.
Gold L; Ayers D; Bertino J; Bock C; Bock A; Brody EN; Carter J; Dalby AB; Eaton BE; Fitzwater T; Flather D; Forbes A; Foreman T; Fowler C; Gawande B; Goss M; Gunn M; Gupta S; Halladay D; Heil J; Heilig J; Hicke B; Husar G; Janjic N; Jarvis T; Jennings S; Katilius E; Keeney TR; Kim N; Koch TH; Kraemer S; Kroiss L; Le N; Levine D; Lindsey W; Lollo B; Mayfield W; Mehan M; Mehler R; Nelson SK; Nelson M; Nieuwlandt D; Nikrad M; Ochsner U; Ostroff RM; Otis M; Parker T; Pietrasiewicz S; Resnicow DI; Rohloff J; Sanders G; Sattin S; Schneider D; Singer B; Stanton M; Sterkel A; Stewart A; Stratford S; Vaught JD; Vrkljan M; Walker JJ; Watrobka M; Waugh S; Weiss A; Wilcox SK; Wolfson A; Wolk SK; Zhang C; Zichi D
PLoS One; 2010 Dec; 5(12):e15004. PubMed ID: 21165148
[TBL] [Abstract][Full Text] [Related]
12. Mass spectrometry-based biomarker discovery: toward a global proteome index of individuality.
Hawkridge AM; Muddiman DC
Annu Rev Anal Chem (Palo Alto Calif); 2009; 2():265-77. PubMed ID: 20636062
[TBL] [Abstract][Full Text] [Related]
13. [Proteomics and biomarkers for detection of ovarian cancer].
Kacerovský M; Tambor V; Lenco J; Tosner J
Ceska Gynekol; 2009 Jun; 74(3):163-70. PubMed ID: 19642513
[TBL] [Abstract][Full Text] [Related]
14. A proteomic signature of ovarian cancer tumor fluid identified by highthroughput and verified by targeted proteomics.
Poersch A; Grassi ML; Carvalho VP; Lanfredi GP; Palma CS; Greene LJ; de Sousa CB; Carrara HHA; Candido Dos Reis FJ; Faça VM
J Proteomics; 2016 Aug; 145():226-236. PubMed ID: 27222041
[TBL] [Abstract][Full Text] [Related]
15. [Molecular diagnostics of ovarian cancer using proteome techniques].
Vlasova MA; Moshkovskiĭ SA; Safarova MP; Makarov OV; Archakov AI
Biomed Khim; 2005; 51(4):367-83. PubMed ID: 16223028
[TBL] [Abstract][Full Text] [Related]
16. Targeted mass spectrometry approaches for protein biomarker verification.
Meng Z; Veenstra TD
J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
[TBL] [Abstract][Full Text] [Related]
17. Emerging Affinity-Based Proteomic Technologies for Large-Scale Plasma Profiling in Cardiovascular Disease.
Smith JG; Gerszten RE
Circulation; 2017 Apr; 135(17):1651-1664. PubMed ID: 28438806
[TBL] [Abstract][Full Text] [Related]
18. Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.
Boja ES; Fehniger TE; Baker MS; Marko-Varga G; Rodriguez H
J Proteome Res; 2014 Dec; 13(12):5325-32. PubMed ID: 25171765
[TBL] [Abstract][Full Text] [Related]
19. Biomarker discovery in mass spectrometry-based urinary proteomics.
Thomas S; Hao L; Ricke WA; Li L
Proteomics Clin Appl; 2016 Apr; 10(4):358-70. PubMed ID: 26703953
[TBL] [Abstract][Full Text] [Related]
20. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation.
Cohen Freue GV; Meredith A; Smith D; Bergman A; Sasaki M; Lam KK; Hollander Z; Opushneva N; Takhar M; Lin D; Wilson-McManus J; Balshaw R; Keown PA; Borchers CH; McManus B; Ng RT; McMaster WR;
PLoS Comput Biol; 2013 Apr; 9(4):e1002963. PubMed ID: 23592955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
